Skip to main content

Table 2 Imaging and Ki-67 results,  n = 40

From: Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients

  Aromatase inhibitor
( n  = 28)
Trastuzumab
( n  = 12)
   n (%) Median
(min, max)
 n (%) Median
(min, max)
SUVmax of index lesion at baseline 28 4.6 (1.6, 18.9) 12 8.9 (2.6, 17.2)
Days between FDG PET scans 28 18 (12, 33) 12 15 (13, 29)
SUVmax of index lesion at follow-up 28 3.2 (1.2, 13.6) 12 5.3 (1.6, 17.1)
Percent change in SUVmax 28 −28 (−60, 11) 12 −25 (−75, 9)
Patients with FDG PET early response (≥20% SUV decline) 20 (71%)   6 (50%)  
Ki-67 prior to run-in therapy (%) 22 15 (<5, 41) 5 40 (5, 60)
Days between successful biopsies 14 51 (16, 608) 3 29 (14, 49)
Ki-67 following run-in therapy (%) 14 5 (0.5, 60) 3 25 (20, 60)
Patients with Ki-67 ≤5% following run-in therapy 11 (79%)   0 (0%)  
Change in Ki-67 14 −8 (−26, 30) 3 0 (−15, 15)